Elutia, Inc. (ELUT) Earnings Call Analysis
NASDAQ · Healthcare · Medical Devices
Earnings Reports
-
ELUT Q1 2026: NXT 41X FDA Pathway Lifts Confidence as 80% Margin Platform Scales
June 17, 2026
-
ELUT Q2 2025: LU Pro Drives 49% Sequential Growth, Margin Expansion Signals Scalable Platform
June 16, 2026
-
Elutia (ELUT) Q3 2025: $88M Divestiture Fuels NXT41X Launch Path and Margin Reset
June 16, 2026
-
Ellucia (ELUT) Q4 2025: Gross Margin Expands 12 Points as Strategic Reset Focuses on 41X Launch
June 15, 2026